Search Results - "Storozhakova, A. E."

RS4673 and pon1 level in blood plasma - new prospects in prediction and early diagnostics of anthracycline-mediated cardiotoxicity by Gvaldin, D Yu, Timoshkina, N N, Vashchenko, L N, Novikova, I A, Vladimirova, L Yu, Storozhakova, A E, Sagakyants, A B

“…The purpose of this study was to research the effectiveness of molecular genetic tests based on the determination of the rs4673 CYBA polymorphism (c.242C>T)…”
Get more information

Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy by Vladimirova, L. Yu, Abramova, N. A., Lyanova, A. A., Storozhakova, A. E., Popova, I. L., Teplyakova, M. A., Tikhanovskaya, N. M., Ryadinskaya, L. A., Kalabanova, E. A., Kabanov, S. N., Udalenkova, I. A.

“…Introduction . Erythropoietin (EPO) application is a pathogenetic method for anemia correction in cancer patients. The purpose of study . Clinical evaluation…”
Get full text

Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment by L. Yu. Vladimirova, E. M. Frantsiyants, N. A. Abramova, K. A. Novoselova, V. S. Myagkova, O. V. Katelnitskaya, A. E. Storozhakova, I. L. Popova, S. N. Kabanov, N. M. Tikhanovskaya, E. A. Kalabanova, L. A. Ryadinskaya, A. A. Lyanova, M. A. Teplyakova, V. R. Zakharchenko, N. K. Guskova

“…Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50…”
Get full text

Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation) by Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Teplyakova, M. A., Tikhanovskaya, N. M., Lianova, A. A., Storozhakova, A. E., Ryadinskaya, L. A., Kabanov, S. N., Kalabanova, E. A.

“…The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed…”
Get full text

Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma by Vladimirova, L. Yu, Storozhakova, A. E., Kalabanova, E. A., Meshcheryakov, P. N., Oskin, S. V., Kabanov, S. N., Samaneva, N. Yu, Svetitskaya, Ya. V., Tishina, A. V.

“…Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced…”
Get full text

Bevacizumab in maintenance therapy for ovarian cancer patients by Vladimirova, L. Yu, Storozhakova, A. E., Kalabanova, E. A., Verenikina, E. V., Kabanov, S. N., Svetitskaya, Ya. V., Samaneva, N. Yu, Tikhanovskaya, N. M., Novoselova, K. A., Selezneva, O. G., Tishina, A. V.

“…Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular…”
Get full text

HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE by Vladimirova, L. Yu, Storozhakova, A. E., Snezhko, T. A., Strakhova, L. K., Abramova, N. A., Kabanov, S. N., Kalabanova, E. A., Samaneva, N. Yu, Svetitskaya, Ya. V., Tishina, A. V.

“…Breast cancer (BC) is the most common female cancer and the first leading cause of cancer death in women. Luminal phenotypes represent about 70% of this…”
Get full text

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER by Kit, O. I., Vladimirova, L. Yu, Kalabanova, E. A., Storozhakova, A. E., Kabanov, S. N., Snezhko, T. A., Mitashok, I. S., Svetitskaya, Ya. V., Samaneva, N. Yu, Kornilova, I. S., Przhedetskiy, Yu. V., Pozdnyakova, V. V., Abramova, N. A., Popova, I. L., Tikhanovskaya, N. M., Lyanova, A. A., Novoselova, K. A., Ryadinskaya, L. A.

“…Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The…”
Get full text

Fulvestrant in treatment for metastatic breast cancer by Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Storozhakova, A. E., Tikhanovskaya, N. M., Novoselova, K. A., L’yanova, A. A., Ryadinskaya, L. A., Ezhova, M. O., Teplyakova, M. A., Strakhov, L. K.

“…Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic…”
Get full text

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy by Lyanova, A. A., Vladimirova, L. Yu, Ulianova, E. P., Storozhakova, A. E., Abramova, N. A., Popova, I. L., Teplyakova, M. A., Tikhanovskaya, N. M., Myagkova, V. S., Novoselova, K. A., Ryadinskaya, L. A., Strakhova, L. K., Kalabanova, E. A.

“…Introduction: Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates…”
Get full text

Dynamics of changes in expression of VEGF neoangiogenic factor in tumor tissue bioptates in patients with squamous cell carcinoma of oral mucosa receiving cetuximab treatment and chemotherapy by A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov

“…Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of…”
Get full text

Blood levels of growth and progression factors in patients with locally advanced breast cancer during neoadjuvant chemotherapy by E. M. Frantsiyants, N. Yu. Samaneva, L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, S. N. Kabanov, A. V. Tishina

“…Purpose of the study. An analysis of blood levels of TGF-β, TGFR2, TNF-α, TNF-αR1, TNF-αR2, CD44 and MMP9 in patients with various biological subtypes of…”
Get full text

The therapeutic features of EGFR L858R exon 21 mutation in non-small cell lung cancer by Mandrina, M. O., Barbolina, T. D., Vladimirova, L. Yu, Storozhakova, A. E., Laktionov, K. K.

“…Introduction. Monotherapy with EGFR tyrosine kinase inhibitors (TKIs) results in a worse prognosis for patients with the exon 21 L858R mutation than for…”
Get full text

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study by Fedyanin, M. Yu, Vladimirova, L. Yu, Abramova, N. A., Storozhakova, A. E., Popova, I. L., Tikhanovskaya, N. M., Kalabanova, E. A., Panina, Е. G., Arzamastseva, A. I., Rybakov, E. G., Bolotina, L. V., Ustinova, T. V., Kachmazov, А. А., Pokataev, I. A., Tryakin, A. A., Sekhina, O. V., Chekini, D. A., Elsnukaeva, Kh. Kh.-M., Podluzhniy, D. V., Tjulandin, S. A., Kit, O. I.

“…Objective: to analyze the frequency of metastasectomy in general population of patients with RAS wild-type metastatic colorectal cancer who received…”
Get full text

Results of treatment of patients with locally advanced and metastatic non-squamous cell non-small-cell lung carcinoma with pemetrexed (by own experience) by Vladimirova, L.Yu, Storozhakova, A.E., Kabanov, S.N., Kalabanova, E.A.

“…Lung cancer is one of the most common malignant tumors. As over 70 % of patients at diagnosis have locally advanced or generalized process, the majority of…”
Get full text

Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy by Vladimirova, L Yu, Mitashok, I S, Storozhakova, A E, Kalabanova, E A, Svetitskaya, Ya V, Kabanov, S N

“…Nausea and vomiting are among adverse effects of chemotherapy that significantly worsen quality of life of patients. 5-HT3 receptor antagonists have been used…”
Get more information

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer by Kit, O.I., Vladimirova, L.Y., Abramova, N.A., Storozhakova, A.E., Popova, I.L., Tikhanovskaya, N.M., Lyaynova, A.A., Ryadinskaya, L.A.

“…The data of the efficacy and safety regorafenib in the treatment of 7 patients with metastatic colorectal cancer (mCRC) refractory to treatment with…”
Get full text

Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy by Vladimirova, L.Yu, Mitashok, I.S., Snezhko, T.A., Samaneva, N.Yu, Storozhakova, A.E., Kornilova, I.S.

“…The main treatment for metastatic soft tissue sarcomas is chemotherapy (CT); neutropenia is its frequent complication that is treated with various colony…”
Get full text

The results of the first retrospective data analysis of eribulin application in patients with metastatic breast cancer in actual clinical practice in Russia by Bolotina, L.V., Manziuk, L.V., Gorbunova, V.A., Kovalenko, E.I.

“…The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic…”
Get full text